Curis to Present at H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00 a.m. ET.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright-bioconnect-conference-301452433.html

SOURCE Curis, Inc.

FAQ

When will Curis present at the H.C. Wainwright BioConnect Conference?

Curis will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET.

How can I watch Curis' presentation at the conference?

The presentation will be available for on-demand viewing on Curis' website under the Investors section.

What are the key pipelines of Curis related to cancer treatment?

Curis is developing several therapeutics, including CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.

What is CA-4948 and in which trials is it involved?

CA-4948 is an IRAK4 kinase inhibitor undergoing testing in Phase 1/2 trials for non-Hodgkin lymphoma and acute myeloid leukemia.

What collaborations does Curis have in oncology?

Curis has collaborations with Aurigene, ImmuNext, and Genentech, focusing on immuno-oncology and precision oncology therapeutics.